Cell-specific genetic medicines

We overcome the biggest challenge for genetic medicines: Safe and effective delivery. We developed a field-leading proprietary technology for systemic nucleic acid delivery, based on scalable non-immunogenic materials. Our data-driven high-throughput platform allows us to screen novel nanocarriers at unparalleled scale.

We use our cell-specific nanocarriers to develop mRNA and gene editing therapies for currently incurable diseases. Our pipeline includes immunotherapies, which we strive to advance rapidly into the clinic.


© 2024 Nuntius Therapeutics.

Nuntius Therapeutics Inc.

United States

Nuntius Therapeutics Ltd.

United Kingdom